Curcumin combining temozolomide formed localized nanogel for inhibition of postsurgical chemoresistant glioblastoma

Aim: To investigate the use of nanoparticle (NP)-encapsulated injectable thermosensitive hydrogelformed
nanogel for inhibition of postsurgical residual temozolomide (TMZ)-resistant glioblastoma (GBM)
recurrence. Materials & methods: Curcumin (Cur) was coloaded with TMZ into PEG-PLGA NPs, then NPs
were further encapsulated into a thermosensitive hydrogel to form a nanogel, which was injected into
the resection cavity of the GBM postsurgery. Results: The prepared nanogel displayed excellent drugloading
capacity and long-term drug release. Estimated survival characteristics demonstrated that the
nanogel could play a significant role in TMZ-resistant tumor inhibition with low drug-induced toxicity.
The originally designed ratio of Cur/TMZ was sustained, making it an effective therapeutic outcome.
Conclusion: Cur-combined TMZ-formed nanogels can be a promising candidate for the local inhibition of
GBM recurrence.

目的：探究包载纳米粒（NP）的可注射温敏水凝胶基纳米凝胶，用于抑制术后残留替莫唑胺（TMZ）耐药胶质母细胞瘤（GBM）复发的应用效果。
材料与方法：将姜黄素（Cur）与替莫唑胺（TMZ）共同载入聚乙二醇-聚乳酸羟基乙酸共聚物纳米粒（PEG-PLGA NP），随后将该纳米粒进一步包埋于温敏水凝胶中制备得到纳米凝胶，并将其注射至GBM术后切除腔内。
结果：所制备的纳米凝胶展现出优异的载药性能与长效释药特性。生存预后评估结果显示，该纳米凝胶可在低药物诱导毒性的前提下，对TMZ耐药肿瘤发挥显著抑制作用。姜黄素与替莫唑胺的初始设计配比得以维持，保障了理想的治疗效果。
结论：姜黄素联合替莫唑胺制备的纳米凝胶，有望成为抑制GBM术后局部复发的极具潜力的候选治疗方案。